Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep

NCT01073930 · View on ClinicalTrials.gov ↗

Study Summary

Subjects undergoing an elective complete colonoscopy will randomly receive either PicoPrep: 2-sachets for oral solution in two divided doses given a night before (first dose - sachet) and approximately 5 hours prior to procedure (second dose - sachet) or HalfLytely: for oral solution and two 5 mg Bisacodyl tablets, given the day before the procedure to evaluate its effectiveness, tolerability and safety.

Conditions Studied

Interventions

  • DRUG PicoPrep
  • DRUG HalfLytely
  • DRUG bisacodyl

Study Locations (9)

Alabama

  • Clinical Research Associates — Huntsville

Arkansas

  • Arkansas Gastroenterology — Sherwood

Connecticut

  • Connecticut Gastroenterology Institute — Bristol

Indiana

  • Indiana University Hospital — Indianapolis

Louisiana

  • Louisiana Research Center LLC — Shreveport

North Carolina

  • Piedmont Medical Research Associates — Winston-Salem

Pennsylvania

  • Hillmont GI, P.C. — Flourtown

Tennessee

  • ClinSearch — Chattanooga

Trial Details

FieldValue
Enrollment Target 608 participants
Start Date 2010-05
Est. Completion 2010-10
Phase Phase 3

Sponsor

Ferring Pharmaceuticals

27 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01073930

The ClinicalTrials.gov registry entry for NCT01073930 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Bowel Preparation appearing as the primary indexed condition, and to 3 interventions — of which PicoPrep is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01073930 reports 9 study locations spanning 9 distinct geographic areas — top geographies include Alabama, Arkansas, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01073930 about?

NCT01073930 is a clinical study titled "Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep". Subjects undergoing an elective complete colonoscopy will randomly receive either PicoPrep: 2-sachets for oral solution in two divided doses given a night before (first dose - sachet) and approximately 5 hours prior to procedure (second dose - sachet) or HalfLytely: for oral solution and two 5 mg Bi...

What is the current status of trial NCT01073930?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 608 participants. The study started on 2010-05. Estimated completion is 2010-10.

What conditions does trial NCT01073930 study?

This clinical trial studies the following conditions: Bowel Preparation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01073930?

The interventions under investigation include: PicoPrep (DRUG), HalfLytely (DRUG), bisacodyl (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01073930?

This trial is sponsored by Ferring Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01073930 being conducted?

This trial has 9 study locations across Alabama, Arkansas, Connecticut, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial